Select the drug indication to add to your list

Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:


Generic Name and Formulations:
Darunavir, cobicistat; 800mg/150mg; tabs.

Janssen Therapeutics

Therapeutic Use:

Indications for PREZCOBIX:

In combination with other antiretroviral agents for treatment of HIV-1 infection in adults with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M T74P, L76V, I84V, L89V).


Take with food. 1 tab daily.


<18yrs: not established.


Concomitant alfuzosin, ranolazine, dronedarone, carbamazepine, phenobarbital, phenytoin, colchicine (in renal/hepatic impaired), rifampin, lurasidone, pimozide, ergots, cisapride, St. John's wort, elbasvir/grazoprevir, lomitapide, lovastatin, simvastatin, oral midazolam, triazolam, sildenafil (for PAH).


Conduct HIV genotypic testing prior to initiation in antiretroviral treatment-experienced; if not feasible, do not initiate in protease inhibitor-experienced patients. Assess CrCl prior to initiation. Renal impairment: consider alternatives that do not require dose adjustments. Monitor closely if confirmed SCr >0.4mg/dL from baseline. When concomitant tenofovir DF: assess baseline CrCl, urine glucose, urine protein and monitor during treatment; if CrCl <70mL/min: not recommended; monitor serum phosphorus if risk of renal impairment. Hepatic impairment (eg, chronic hepatitis, cirrhosis, pre-treatment elevated transaminases): monitor liver enzymes; interrupt or discontinue therapy if liver dysfunction occurs or worsens. Severe hepatic impairment: not recommended. Sulfonamide allergy. Diabetes (may need insulin or oral hypoglycemics dose adjusted). Hemophilia. Elderly. Pregnancy (use alternatives), nursing mothers: not recommended.

Pharmacological Class:

HIV-1 protease inhibitor + CYP3A inhibitor.


See Contraindications. Concomitant tenofovir DF with concomitant or recent nephrotoxic agents, darunavir- or cobicistat-containing products, ritonavir, or other antiretrovirals that require PK boosting (eg, another protease inhibitor, elvitegravir), efavirenz, etravirine, nevirapine, apixaban (see full labeling), rivaroxaban, voriconazole, rifapentine, simeprevir, everolimus, salmeterol, avanafil, ticagrelor: not recommended. May need to adjust dose of dasatinib, nilotinib, colchicine, sildenafil, tadalafil, vardenafil, perphenazine, risperidone, thioridazine, buprenorphine, buprenorphine/naloxone, methadone, tramadol, bosentan, rifabutin, and other sedatives/hypnotics. Concomitant maraviroc: give maraviroc 150mg twice daily. Concomitant quetiapine: consider alternative antiretrovirals; if necessary, reduce quetiapine to ⅙ of current dose and monitor. Monitor with antiarrhythmics, digoxin, warfarin, clonazepam, SSRIs, TCAs, trazodone, antimalarials (eg, artemether, lumefantrine), itraconazole, ketoconazole, fentanyl, oxycodone, immunosuppressants, β-blockers, calcium channel blockers. Concomitant other statins (eg, atorvastatin (max 20mg/day), fluvastatin, pitavastatin, pravastatin, rosuvastatin (max 20mg/day): start at low dose, titrate and monitor. Concomitant antibacterials (eg, clarithromycin, erythromycin, telithromycin), CYP3A-inducing anticonvulsants that are not contraindicated (eg, eslicarbazepine, oxcarbazepine), CYP3A-inducing corticosteroids (eg, systemic dexamethasone or others): consider alternatives. Concomitant vincristine, vinblastine: consider temporarily withholding cobicistat-containing regimen if significant hematologic or GI adverse events develop. Concomitant hormonal contraceptives (eg, drosperinone): monitor for hyperkalemia; estrogen-containing contraceptives: consider additional or alternative (non-hormonal) contraception. Separate dosing of didanosine at least 1hr before or 2hrs after. See full labeling.

Adverse Reactions:

Diarrhea, nausea, rash, headache, abdominal pain, vomiting; severe skin reactions (discontinue if occurs), fat redistribution, immune reconstitution syndrome.


To register pregnant patients exposed to Prezcobix, call (800) 258-4263.

Generic Availability:


How Supplied:


Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs